Sangamo Therapeutics Inc (NASDAQ:SGMO)

23.30
Delayed Data
As of Feb 16
 +0.30 / +1.30%
Today’s Change
3.65
Today|||52-Week Range
23.75
+42.07%
Year-to-Date
Biotech Gold Rush Starts to Pick Up; Xerox, Fujifilm Saga Continues -- ICYMI
Feb 14 / TheStreet.com - Paid Partner Content
Focused on Two Sectors
Feb 13 / TheStreet.com - Paid Partner Content
Biotech Heats Up as Fear of Missing Out Returns
Feb 14 / TheStreet.com - Paid Partner Content
Indexes Are Holding Up Well, For Now
Feb 12 / TheStreet.com - Paid Partner Content
Seeing Good Action in Several Stocks, Buying More MJ, Gold
Feb 14 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close23.00
Today’s open23.15
Day’s range22.75 - 23.75
Volume1,889,801
Average volume (3 months)1,506,483
Market cap$2.0B
Data as of 4:00pm ET, 02/16/2018

Growth & Valuation

Earnings growth (last year)-75.86%
Earnings growth (this year)+29.09%
Earnings growth (next 5 years)+24.50%
Revenue growth (last year)-50.96%
P/E ratioNM
Price/Sales11.10
Price/Book12.12

Competitors

----
EPZMEpizyme Inc-0.50-2.68%
FPRXFive Prime Therapeut...-0.41-2.19%
MNTAMomenta Pharmaceutic...-0.05-0.31%
Data as of 4:00pm ET, 02/16/2018

Financials

Last reporting dateFebruary 7, 2018
EPS forecast (this quarter)-$0.18
Annual revenue (last year)$19.4M
Annual profit (last year)-$71.7M
Net profit margin-369.58%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Alexander Macrae
Chief Financial Officer &
Senior Vice President
Kathy Yi
Corporate headquarters
Richmond, California

Forecasts